Title: HexAgon-HN: Phase 2/3 Study of the Hexavalent OX40 Agonist INBRX-106 as an Add-On to Pembrolizumab in First-Line Recurrent/Metastatic PD-L1+ (Combined Positive Score ≥20) Head and Neck Cancer
Lead Author: Dan P. Zandberg
Abstract: 651
Location: George R. Brown Convention Center, Houston, TX - Level 1 – Exhibit Halls AB

Trial-in-progress poster presentation on Friday, November 8, 2024 from 12:15-1:45 PM CST and 5:30-7:00 PM CST

Title: CD8+ T cells play a critical role in novel hexavalent OX40 agonist treatment to favor anti-tumor immunity
Lead Author: Nisha Holay
Abstract: 1301
Location: George R. Brown Convention Center, Houston, TX - Level 1 – Exhibit Halls AB

Poster presentation on Friday, November 8, 2024 from 12:15-1:45 PM CST and 5:30-7:00 PM CST

Title: Phase 1/2 Study of the Bispecific 4-1BB and PD-L1 Antibody INBRX-105 Alone and in Combination With Pembrolizumab in Select Solid Tumors
Lead Author: Jong Chul Park, MD
Abstract: 742
​Location: San Diego Convention Center, San Diego, CA - Hall A

Trial-in-progress poster presentation on Saturday, November 4^th, 2023 from 9 AM – 8:30 PM Pacific Standard Time

Title: Phase 1/2 Study of the Hexavalent OX40 Agonist INBRX-106 Alone and in Combination With Pembrolizumab in Select Solid Tumors
Lead Author: Rachel E. Sanborn, MD
Abstract: 748
Location: San Diego Convention Center in San Diego, CA - Hall A

Trial-in-progress poster presentation on Saturday, November 4^th, 2023 from 9 AM – 8:30 PM Pacific Standard Time

Title: The Tetravalent Death Receptor 5 Agonist INBRX-109 Combined With Chemotherapy in Ewing Sarcoma: Preliminary Data From A Phase 1 Study
Lead Author: Rashmi Chugh, MD
Location:  The Liffey Convention Centre in Dublin, Ireland

Poster presentation on Thursday, November 2^nd, 2023 from 5:30 PM – 6:30 PM Irish Standard Time